Story
Dr. Reddy's Shares Rise on Takeda Dengue Vaccine Distribution Deal
Summary
The pharmaceutical company's stock gained after announcing an agreement to distribute Takeda's Qdenga, the first dengue vaccine approved for use in India.
Shares of Dr. Reddy’s Laboratories (NYSE:RDY) rose on Friday after the company announced a distribution agreement with Japanese drugmaker Takeda Pharmaceutical for its dengue vaccine, Qdenga.
The Agreement
Under the terms of the deal, Dr. Reddy’s will promote and distribute the Qdenga vaccine within India. The partnership is significant as Qdenga is the first-ever dengue vaccine to receive regulatory approval in the country.
The vaccine has been approved for use in both children and adults. According to the announcement, Dr. Reddy's anticipates that Qdenga will be commercially available in India during the first half of 2027.
Market Reaction
AdFollowing the news, Dr. Reddy’s stock climbed 1.8% to close at ₹1,196 in trading on India's National Stock Exchange. The company's shares outperformed the broader Indian market, as the benchmark Nifty 50 index posted a modest gain of just 0.1% during the same session.
Context for Investors
The deal positions Dr. Reddy's to tap into a critical public health need in India, where dengue fever is a widespread concern. The introduction of the country's first approved vaccine represents a potentially significant new market for the company, though revenue contributions are not expected until the planned 2027 launch.
Read next
More on Stocks
UBS Lifts AI Spending Forecast to $1.4 Trillion by 2027, Cites Soaring Memory Costs
UBS has dramatically raised its forecast for artificial intelligence capital expenditure, projecting it will reach nearly $1 trillion this year and $1.4 trillion in 2027, driven almost entirely by surging memory prices.
CFDA CEO Steven Kolb Resigns Following Physical Altercation with Protesters
Steven Kolb has stepped down as CEO of the Council of Fashion Designers of America after twenty years, following a widely publicized incident where he physically restrained animal rights activists at a New York Fashion Week show.
Anthropic Weighs New AI Model Release to Counter OpenAI Ahead of IPO, Sources Say
AI developer Anthropic is reportedly considering a new model launch to compete with OpenAI's recent success, a move that comes as the company prepares for an IPO and shortly after its CEO advocated for a slowdown in AI development.
Paramount, States Discuss CNN Oversight in Warner Bros. Merger Settlement Talks, Sources Say
Paramount and a dozen states are reportedly discussing a settlement to clear its $110 billion acquisition of Warner Bros. Discovery, with potential terms including independent monitoring of CNN and a commitment to theatrical film releases.